



INNOVATIVE RESEARCH GRANT IN MACULAR DEGENERATION RESEARCH

A PROGRAM OF BRIGHTFOCUS FOUNDATION

Letter of Intent Guidelines

Due by 5:00 PM EST (Washington, D.C.)

Scope

The goal of the BrightFocus Foundation research grants program is to advance innovative research promoting advances in the etiology, prevention, and treatments of Alzheimer’s disease, macular degeneration, and glaucoma. Our vision is to help people live free from diseases of mind and sight. The Foundation is interested in supporting high risk studies that illuminate areas for which there currently is little understanding, helping to bring to light crucial knowledge about these three devastating diseases.

The BrightFocus funding mechanisms are designed to provide initial funding for highly innovative experimental ideas, including interdisciplinary investigations that may apply to two or three of the above-mentioned diseases. Most of the awardees use the BrightFocus donor award money to demonstrate key findings that lead to later interest and additional funding from industrial or governmental funding agencies. BrightFocus prefers not to fund projects for which substantial resources already exist, or that may already be competitive for governmental or industrial support.

Overview

This program is intended to provide support for high-risk/high-gain age-related macular degeneration research. We hope to attract established investigators to apply for this support, but the aims of the application must contain outside-the-box ideas that are novel in the field. BrightFocus will not consider applications that are only a derivative of the research already ongoing in the laboratory of the applicant, if they are currently in the macular degeneration field. Applicants who are experts in another field are encouraged to apply their talents to proposing innovative research in the macular degeneration field. Hopefully multiple awards in this category can be made each year, but BrightFocus will decline to make an award in this category in years when the scientific review panel decides that sufficiently novel research applications have not been proposed. Successful applicants will receive \$600,000, payable across three years, pending a successful mid-point review showing substantial progress on the specific aims of the proposal.

Award Amount: \$200,000 per year (total value \$600,000)

Duration: up to 3 years

Eligibility

Specific eligibility criteria include:

- Candidates must hold an MD, PhD, DVM, DO, OD or equivalent degree
- Applicant must serve as the Principal Investigator on the project and have independent laboratory space
- While some of the grant can be used to support salary for the PI, the percent requested should be limited to the lesser of 35% of the total grant request, or 35% of the individual's salary. Co-PI salaries are capped at the lesser of 25% of the total grant request, or 25% of the individual's salary. Note: Postdoctoral fellows should not be named as Co-PI on Innovative Research awards but should instead apply for the MDR Postdoctoral fellowship.
- Applicants may currently be working in a non-profit, governmental, academic research institution, or at a for-profit including start-up and biotech institution
- Previous recipients of this award are not eligible

General Guidelines

- Submit your Letter of Intent using the template provided in the application portal
- Use Times New Roman font at a size no less than 11 points
- Use margins no less than 3/4" on all sides
- The color of the narrative text should be black
- Applications must be legible and written in English
- Do not use jargons or unusual abbreviations
- Maximum character and/or page counts for individual sections will be enforced.
- File size cannot exceed greater than 10 MB of information

New Guidelines for Certain Reagents and Techniques:

RPE cultures used in research proposals:

Because the RPE is a primary tissue target in AMD, BrightFocus frequently receives applications that request support for studies that rely entirely or in part on tissue culture preparations to model the RPE. The review committee has been critical of proposals that solely rely on ARPE-19 cells, due in part to the fact that this spontaneously transformed cell line does not have the full range of RPE-specific features when not cultured for sufficient time to allow for epithelial differentiation. However, if epithelial mesenchymal transformation (EMT) is being examined in the context of AMD, alternative culture protocols may be justified. Multiple methods are now available for generating fully differentiated RPE cultures using cells isolated from fetal and adult eyes, or differentiated from induced stem cells. Whatever model is chosen, we expect the applicant to fully justify the choice(s) and to provide evidence that the model used has well differentiated RPE-specific characteristics. Validation of results using multiple models is encouraged. Each human RPE line or iPSC line proposed for use in a BrightFocus application must be screened for the statistically-significant AMD risk SNP's in the CFH, C2, C3 and ARMS2/HTRA1 loci.

Human Samples and Human Subjects used in research proposals:

Applicants submitting research proposals to BrightFocus that use human tissues or propose patient-based AMD analysis should include genetic testing for AMD genetic risk loci. This includes studies that involve individuals, human samples, and/or human-derived cells or tissues. Even if the studies proposed are not contingent on analysis of genetic variants, it is important that data generated from BrightFocus research funds be suitable for collaborative and meta-analysis studies in the future. Genetic screening should at a minimum include the

statistically-significant risk SNP's in the CFH, C2, C3 and ARMS2/HTRA1 loci. Such genetic testing is now available from several clinical laboratories. Funding in the current and future review cycles of each BrightFocus grant will be contingent on evidence that the genotyping will/has been done and that this genetic data is included in publications resulting from BrightFocus funding making it available to other investigators.

VIEW SLIDESHARE VIDEOS FROM BRIGHTFOCUS MACULAR FAST TRACK 2021:

BrightFocus organized and sponsored the inaugural BrightFocus Macular Fast Track workshop in September 2021 which was an immersive learning opportunity specifically created for scientists who are starting or contemplating a career in macular degeneration research. Please visit our website for the program and links to view recordings of the presentations, which include insights into the current state of macular degeneration research, specifically in reference to animal models and techniques (<https://science.brightfocus.org/event/macular-fast-track>)

Submission Instructions

All applications must be completed through our online portal. To access the application portal, click on the text “application portal to apply online” on the BrightFocus website at:

<http://brightfocus.org/research/apply/main.html>, where you will be taken to a registration and login page.

You MUST complete ALL of the sections in your application. Applications that are incomplete or fail to adhere to formatting instructions **will be DECLINED without review.**

Section 1

Title Page

This section of the application asks for Project Title (maximum 150 characters), Keywords (provide up to 5 keywords for this application), Project duration, Project budget (total award amount requested), if this is a resubmission of proposal declined in the previous year, please indicate and provide a response to prior critique/changes from previous submission (maximum 1250 characters), and information on submission of this application to other granting organization.

Section 2

Download Templates and Instructions

This section contains Research Plan and Biographical Sketch that are required to complete, or which might be necessary for the full submission of your application. You MUST use the “Research Plan” template provided in this section for submission.

Section 3

Enable Other Users to Access this Proposal

This section is used specifically for providing access rights to other people whom you may wish to have access to your application. You may choose their access as “View” or “Edit.” If you give someone “Edit” ability they can upload documents or add attachments in your absence.

If you mark an individual as “Auto Notify” this means each time an email is sent to you through proposalCENTRAL, that person will automatically receive a copy of the email.

Section 4

Applicant/PI

This section of the application asks for the Principal Investigator's information. All fields that are marked with asterisk (*) are required fields. If you already have a professional profile within proposalCENTRAL, these fields will be automatically populated and filled in. Please review them carefully to confirm the information is correct.

Section 5

Institution

This section contains the information of the "Lead Institution." This page defaults to the institution of the Principal Investigator. If the institution is incorrect, you may click on the "Change Institution" button and search for the correct institution.

Section 6

Key Personnel

ALL personnel working, collaborating, over-seeing or coordinating on the project MUST be listed in this section. This section should also include all collaborators and consultants. You will need to insert their email address in the space provided and click "Add." Complete all required fields and click "Save" when completed. This person will now appear in the "Key Personnel" window.

Section 7

Specific Aims (2400 characters maximum):

Please number and list the proposed specific aims. State the objectives and the hypotheses to be tested and describe concisely and realistically what the specific research described in this application is intended to accomplish. Please note that this section should not include figures, tables, photographs, or other non-text information.

Impact Statement (3500 characters maximum)

Please state how this project will promote major advancement in the understanding of macular degeneration, accelerate treatments and cures. This statement will play a major role in the review of your application and must contain outside-the-box ideas that are novel in the field. Please note that this section should not include figures, tables, photographs, or other non-text information.

Research Category

Please select the Research Category appropriate to the proposed project. BrightFocus does not weight its funding preferentially towards or against any of the listed categories. Your choices will not influence the likelihood of funding. Responses to the fields are used to aid in the selection of appropriate reviewers for the proposal.

Conflict of Interest Self-Report

Depending on the breadth of expertise required to review the applications received in the present review cycle, a subset of the listed researchers may serve on the review committee that evaluates your proposal. For the present review cycle, please note that additional reviewers may be brought onto the review committee if additional expertise is required. Referring to the list provided, please select any individuals with whom the PI of this proposal has any conflict (co-published within preceding 3 years, co-employed or a recent trainee).

Section 8

Conflict of Interest Self-Report

If you declared conflicts on the preceding page, list each reviewer by last name and indicate the type of conflict (co-published within preceding 3 years, co-employed or a recent trainee).

Section 9

Organization Assurance

Please indicate if the proposed research will involve the use of human or vertebrate animal subjects. A signed release from the appropriate committee of the Grantee Institution must be provided to BrightFocus, to demonstrate approval of the proposed research protocol(s) before Grant Award funds are released.

Section 10

Required Attachments

Proposed Research (three-page maximum, 8.5” x 11” page with 3/4” margins, 11 pt Times New Roman font):

This must include a description of the objectives and hypothesis, as well as a summarized version of the experimental design and any preliminary results. This award is intended to foster exceptionally creative projects. The proposed work should not represent incremental advancements of existing lines of inquiry. Please include a statement addressing what you believe to be innovative about the proposed research, and how the project will benefit the age-related macular degeneration field. Please include the origins of major non-commercial reagents for the study, predicted sample sizes, and power calculations, where appropriate. Tables, graphs, and photographs may be included, but are considered to contribute to the page limitations.

Literature Cited: (single page maximum, 8.5” x 11” page with 3/4” margins, 11 pt Times New Roman font):

The Research Plan should not exceed 4 pages when printed on 8.5” x 11” paper. After completing please convert your Letter of Intent Research Plan to a text-accessible pdf file format, save it as “lastname_LOI_Innovative Research_FY24.pdf” where ‘lastname’ is the surname of the Principal Investigator, and upload onto the online portal.

Principal Investigator Biographical Sketch:

Provide a Biographical Sketch for the Principal Investigator. You may replace this section with a NIH Biosketch already in your possession.

Section 11

PI Data Sheet

The information in this section is not mandatory and is only for the use of BrightFocus Foundation for applicant statistics.

Section 12

Validate

AFTER you have validated the document you MUST click “SUBMIT” for the application to be submitted. Validating the document DOES NOT submit the application to BrightFocus Foundation. Proceed to Section 14 for Submitting the application.

Reviews:

Letters of Intent are reviewed and scored on the basis of scientific merit and relevance to the treatment and prevention of age-related macular degeneration. Each proposal is examined by 3-5 reviewers, who are themselves active researchers in the field. A roster of the pool of reviewers currently used by BrightFocus is available at

<https://www.brightfocus.org/grants/frequently-asked-questions#mdr3>. Grants are awarded on the basis of the scientific merit of the proposed research and the relevance of the research to improving our understanding of these diseases. A full description of the review process and outcomes is available at <https://www.brightfocus.org/grants/frequently-asked-questions#mdr3>

Notification:

Written critiques will not be provided during the Letter of Intent stage. The deadline for the full submission is described on the BrightFocus website <http://www.brightfocus.org/research/apply/main.html>. You will be notified in the beginning of September as to whether your Letter of Intent will result in an invitation to submit a full application. Notifications are sent via email.

Contact Information

If you have any questions regarding the program, please contact the BrightFocus scientific affairs department at researchgrants@brightfocus.org.

If you have any difficulties with the application portal, please contact proposalCENTRAL at pcsupport@altum.com or during normal business hour (8:30am - 5:00pm Eastern Time, Monday through Friday) by phone (toll-free): 800 875 2562 (Toll-free U.S. and Canada) or +1 703 964 5840 (Direct Dial International).